
    
      This is a 12-week randomized, double-blind, placebo-controlled, parallel group design trial
      to evaluate the safety and efficacy of inhaled PPP011 on physical functioning and cachexia
      progression in patients with cachexia related to advanced incurable cancer.
    
  